Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections : A real-life experience
del Campo, José A. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Parra-Sánchez, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Figueruela, Blanca (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
García-Rey, Silvia (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Quer, Josep 1963- (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Gregori i Font, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Bernal, Samuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Grande, Lourdes (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Palomares, José C. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Romero-Gómez, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Universitat Autònoma de Barcelona

Date:	2018
Abstract:	The effectiveness of the new generation of hepatitis C treatments named direct-acting antiviral agents (DAAs) depends on the genotype, subtype, and resistance-associated substitutions present in individual patients. The aim of this study was to evaluate a massive sequencing platform for the analysis of genotypes and subtypes of hepatitis C virus (HCV) in order to optimize therapy. A total of 84 patients with hepatitis C were analyzed. The routine genotyping methodology for HCV used at the study institution (Versant HCV Assay, LiPA) was compared with a deep sequencing platform (454/GS-Junior and Illumina MiSeq). The mean viral load in these HCV patients was 6. 89 × 10 6 ± 7. 02 × 10 5. Viral genotypes analyzed by LiPA were distributed as follows: 26% genotype 1a (22/84), 55% genotype 1b (46/84), 1% genotype 1 (1/84), 2. 5% genotype 3 (2/84), 6% genotype 3a (5/84), 6% genotype 4a/c/d (5/84). When analyzed by deep sequencing, the samples were distributed as follows: 27% genotype 1a (23/84), 56% genotype 1b (47/84), 8% genotype 3a (7/84), 5% genotype 4d (4/84), 2. 5% genotype 4f (2/84). Six of the 84 patients (7%) were infected with more than one subtype. Among these, 33% (2/6) failed DAA-based triple therapy. The detection of mixed infection could explain some treatment failures. Accurate determination of viral genotypes and subtypes would allow optimal patient management and improve the effectiveness of DAA therapy.
Grants:	Instituto de Salud Carlos III PI14-01349 Instituto de Salud Carlos III PI16-00337
Note:	Altres ajuts: This work was supported by grants from the Andalusian Government (#PI0892-2012) and co-financed by the European Regional Development Fund (ERDF).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	HCV ; Mixed infection ; Deep sequencing ; NGS ; Direct-acting antivirals
Published in:	International journal of infectious diseases, Vol. 67 (february 2018) , p. 114-117, ISSN 1878-3511

DOI: 10.1016/j.ijid.2017.12.016
PMID: 29253705

None, 17.3 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles